Pharma

Small negative movement today; overall recent volatility with headlines around US tariffs earlier and company-specific trading activity. What it means: Pharma companies can be sensitive to U.S. policy (tariffs/regulatory), patent outcomes and drug approvals. News can move prices quickly. Beginner takeaway: Pharma is research-driven — treat as medium/long-term after checking product pipelines and US exposure. Action: Read company disclosures on US business and approvals; avoid buying purely on headline dips. Risk note: Regulatory or patent setbacks can cause sharp falls.